Dupilumab plus standard care for severe COPD flare-ups
Treatments studied
Part of Lungs & breathing clinical trials.
This study tests whether adding dupilumab (a biologic medication that reduces inflammation) to standard treatment after a severe COPD flare-up requiring hospitalization helps prevent future flare-ups and improves breathing. You may qualify if you were recently hospitalized for COPD with elevated immune markers and have not received certain similar biologic medications recently.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of COPD (chronic obstructive pulmonary disease, a lung condition)
- You were hospitalized or in the emergency department for more than 24 hours due to a COPD flare-up and treated with steroid medications
- Your blood showed elevated eosinophils (a type of white blood cell) during the current flare-up
- You do not have pneumonia or other complicating lung conditions in the past 8 weeks
- You have not received other biologic medications for inflammation within the last 6 months
- You were not on a breathing machine (mechanical ventilation) during your hospital stay
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well dupilumab works over time for people with COPD who still have symptoms despite standard treatments and who have a certain type of inflammation (elevated eosinophils). It uses data from regular doctor visits and patient questionnaires to understand real-world benefits and safety.
This study looks at how well dupilumab works for people with uncontrolled COPD who have high levels of a certain white blood cell (eosinophils). It collects information from routine doctor visits to see how patients feel and if the treatment is safe.
This study tests if a drug called dupilumab, given as a shot under the skin, can reduce airway inflammation in people aged 40-85 with moderate-to-severe COPD who also have signs of a specific type of inflammation called Type 2. It may help if you have frequent flare-ups and are already using multiple inhalers.
This is a registry—an observational study tracking patients with COPD (chronic lung disease) who are newly starting a medication called dupilumab. Researchers will follow your health outcomes to learn how well this treatment works in real-world practice.
This study tests a new way to monitor severe asthma that is driven by high levels of inflammation (T2-high). It involves a bronchoscopy (a thin tube to look inside your lungs) to see how well the treatment is working.
This study tests whether dupilumab improves how well mucus is cleared from the airways in adults with moderate to severe asthma. It may help find better ways to reduce mucus-related breathing problems in people with a specific asthma type.
Hear when a new Chronic Obstructive Pulmonary Disease (COPD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.